Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study

BACKGROUND: Patients with Crohn’s disease (CD) experience intestinal inflammation. Ontamalimab (SHP647), a fully human immunoglobulin G(2) monoclonal antibody against mucosal addressin cell adhesion molecule-1, is a potential novel CD treatment. OPERA II, a multicenter, open-label, phase 2 extension...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Haens, Geert R, Reinisch, Walter, Lee, Scott D, Tarabar, Dino, Louis, Edouard, Kłopocka, Maria, Klaus, Jochen, Schreiber, Stefan, Il Park, Dong, Hébuterne, Xavier, Nagy, Peter, Cataldi, Fabio, Martin, Steven W, Nayak, Satyaprakash, Banerjee, Anindita, Gorelick, Kenneth J, Sandborn, William J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247846/
https://www.ncbi.nlm.nih.gov/pubmed/34427633
http://dx.doi.org/10.1093/ibd/izab215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247846/
https://www.ncbi.nlm.nih.gov/pubmed/34427633
http://dx.doi.org/10.1093/ibd/izab215

Ejemplares similares